nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—Clobetasol propionate—psoriasis	0.211	0.303	CbGbCtD
Dexmedetomidine—CYP1A1—Methoxsalen—psoriasis	0.111	0.159	CbGbCtD
Dexmedetomidine—CYP1A2—Clobetasol propionate—psoriasis	0.0943	0.135	CbGbCtD
Dexmedetomidine—CYP1A1—Cholecalciferol—psoriasis	0.0734	0.105	CbGbCtD
Dexmedetomidine—CYP1A2—Methoxsalen—psoriasis	0.0495	0.0711	CbGbCtD
Dexmedetomidine—CYP2D6—Hydroxyurea—psoriasis	0.0446	0.064	CbGbCtD
Dexmedetomidine—CYP1A1—Dexamethasone—psoriasis	0.0318	0.0456	CbGbCtD
Dexmedetomidine—CYP2D6—Cholecalciferol—psoriasis	0.027	0.0388	CbGbCtD
Dexmedetomidine—CYP2E1—Dexamethasone—psoriasis	0.0245	0.0352	CbGbCtD
Dexmedetomidine—CYP2D6—Cyclosporine—psoriasis	0.0178	0.0255	CbGbCtD
Dexmedetomidine—CYP2D6—Dexamethasone—psoriasis	0.0117	0.0168	CbGbCtD
Dexmedetomidine—Anaemia—Cyclosporine—psoriasis	0.000234	0.000844	CcSEcCtD
Dexmedetomidine—Agitation—Cyclosporine—psoriasis	0.000232	0.000839	CcSEcCtD
Dexmedetomidine—Arrhythmia—Hydrocortisone—psoriasis	0.000231	0.000833	CcSEcCtD
Dexmedetomidine—Nausea—Acitretin—psoriasis	0.000231	0.000832	CcSEcCtD
Dexmedetomidine—Nausea—Fluocinolone Acetonide—psoriasis	0.00023	0.00083	CcSEcCtD
Dexmedetomidine—Anaemia—Mycophenolate mofetil—psoriasis	0.000228	0.000823	CcSEcCtD
Dexmedetomidine—Dyspnoea—Mycophenolic acid—psoriasis	0.000228	0.000821	CcSEcCtD
Dexmedetomidine—Somnolence—Mycophenolic acid—psoriasis	0.000227	0.000819	CcSEcCtD
Dexmedetomidine—Agitation—Mycophenolate mofetil—psoriasis	0.000227	0.000818	CcSEcCtD
Dexmedetomidine—Mental disorder—Hydrocortisone—psoriasis	0.000226	0.000817	CcSEcCtD
Dexmedetomidine—Malnutrition—Hydrocortisone—psoriasis	0.000225	0.000811	CcSEcCtD
Dexmedetomidine—Bradycardia—Dexamethasone—psoriasis	0.000225	0.000811	CcSEcCtD
Dexmedetomidine—Bradycardia—Betamethasone—psoriasis	0.000225	0.000811	CcSEcCtD
Dexmedetomidine—Haemoglobin—Betamethasone—psoriasis	0.000222	0.0008	CcSEcCtD
Dexmedetomidine—Haemoglobin—Dexamethasone—psoriasis	0.000222	0.0008	CcSEcCtD
Dexmedetomidine—Haemorrhage—Betamethasone—psoriasis	0.000221	0.000796	CcSEcCtD
Dexmedetomidine—Haemorrhage—Dexamethasone—psoriasis	0.000221	0.000796	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00022	0.000795	CcSEcCtD
Dexmedetomidine—Hallucination—Dexamethasone—psoriasis	0.00022	0.000792	CcSEcCtD
Dexmedetomidine—Hallucination—Betamethasone—psoriasis	0.00022	0.000792	CcSEcCtD
Dexmedetomidine—Convulsion—Cyclosporine—psoriasis	0.000219	0.000791	CcSEcCtD
Dexmedetomidine—Hypertension—Cyclosporine—psoriasis	0.000218	0.000788	CcSEcCtD
Dexmedetomidine—Constipation—Mycophenolic acid—psoriasis	0.000218	0.000788	CcSEcCtD
Dexmedetomidine—Pain—Mycophenolic acid—psoriasis	0.000218	0.000788	CcSEcCtD
Dexmedetomidine—Arrhythmia—Triamcinolone—psoriasis	0.000217	0.000784	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Prednisone—psoriasis	0.000217	0.000782	CcSEcCtD
Dexmedetomidine—Anxiety—Cyclosporine—psoriasis	0.000215	0.000775	CcSEcCtD
Dexmedetomidine—Convulsion—Mycophenolate mofetil—psoriasis	0.000214	0.000772	CcSEcCtD
Dexmedetomidine—Hypertension—Mycophenolate mofetil—psoriasis	0.000213	0.000769	CcSEcCtD
Dexmedetomidine—Visual impairment—Betamethasone—psoriasis	0.000213	0.000767	CcSEcCtD
Dexmedetomidine—Visual impairment—Dexamethasone—psoriasis	0.000213	0.000767	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Prednisone—psoriasis	0.000211	0.000762	CcSEcCtD
Dexmedetomidine—Dry mouth—Cyclosporine—psoriasis	0.000211	0.00076	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Mycophenolic acid—psoriasis	0.00021	0.000759	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Prednisone—psoriasis	0.00021	0.000757	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Prednisone—psoriasis	0.00021	0.000757	CcSEcCtD
Dexmedetomidine—Anxiety—Mycophenolate mofetil—psoriasis	0.000209	0.000756	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000209	0.000753	CcSEcCtD
Dexmedetomidine—Diarrhoea—Hydroxyurea—psoriasis	0.000208	0.000752	CcSEcCtD
Dexmedetomidine—Confusional state—Cyclosporine—psoriasis	0.000208	0.000751	CcSEcCtD
Dexmedetomidine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000205	0.000742	CcSEcCtD
Dexmedetomidine—Infection—Cyclosporine—psoriasis	0.000205	0.00074	CcSEcCtD
Dexmedetomidine—Confusional state—Mycophenolate mofetil—psoriasis	0.000203	0.000733	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Cyclosporine—psoriasis	0.000202	0.00073	CcSEcCtD
Dexmedetomidine—Abdominal pain—Mycophenolic acid—psoriasis	0.000202	0.000728	CcSEcCtD
Dexmedetomidine—Body temperature increased—Mycophenolic acid—psoriasis	0.000202	0.000728	CcSEcCtD
Dexmedetomidine—Dizziness—Hydroxyurea—psoriasis	0.000202	0.000727	CcSEcCtD
Dexmedetomidine—Angiopathy—Betamethasone—psoriasis	0.0002	0.000723	CcSEcCtD
Dexmedetomidine—Angiopathy—Dexamethasone—psoriasis	0.0002	0.000723	CcSEcCtD
Dexmedetomidine—Infection—Mycophenolate mofetil—psoriasis	0.0002	0.000722	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Cyclosporine—psoriasis	0.0002	0.00072	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisolone—psoriasis	0.000199	0.00072	CcSEcCtD
Dexmedetomidine—Hypertension—Prednisolone—psoriasis	0.000199	0.000717	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000197	0.000712	CcSEcCtD
Dexmedetomidine—Arrhythmia—Dexamethasone—psoriasis	0.000197	0.000711	CcSEcCtD
Dexmedetomidine—Arrhythmia—Betamethasone—psoriasis	0.000197	0.000711	CcSEcCtD
Dexmedetomidine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000197	0.000709	CcSEcCtD
Dexmedetomidine—Bradycardia—Prednisone—psoriasis	0.000196	0.000706	CcSEcCtD
Dexmedetomidine—Convulsion—Hydrocortisone—psoriasis	0.000195	0.000703	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000195	0.000703	CcSEcCtD
Dexmedetomidine—Hypertension—Hydrocortisone—psoriasis	0.000194	0.000701	CcSEcCtD
Dexmedetomidine—Vomiting—Hydroxyurea—psoriasis	0.000194	0.000699	CcSEcCtD
Dexmedetomidine—Haemoglobin—Prednisone—psoriasis	0.000193	0.000697	CcSEcCtD
Dexmedetomidine—Haemorrhage—Prednisone—psoriasis	0.000192	0.000694	CcSEcCtD
Dexmedetomidine—Rash—Hydroxyurea—psoriasis	0.000192	0.000693	CcSEcCtD
Dexmedetomidine—Dermatitis—Hydroxyurea—psoriasis	0.000192	0.000693	CcSEcCtD
Dexmedetomidine—Hallucination—Prednisone—psoriasis	0.000191	0.00069	CcSEcCtD
Dexmedetomidine—Headache—Hydroxyurea—psoriasis	0.000191	0.000689	CcSEcCtD
Dexmedetomidine—Anxiety—Hydrocortisone—psoriasis	0.000191	0.000688	CcSEcCtD
Dexmedetomidine—Hypotension—Mycophenolate mofetil—psoriasis	0.000188	0.000679	CcSEcCtD
Dexmedetomidine—Dyspnoea—Cyclosporine—psoriasis	0.000184	0.000664	CcSEcCtD
Dexmedetomidine—Somnolence—Cyclosporine—psoriasis	0.000184	0.000662	CcSEcCtD
Dexmedetomidine—Convulsion—Triamcinolone—psoriasis	0.000183	0.000662	CcSEcCtD
Dexmedetomidine—Tachycardia—Prednisolone—psoriasis	0.000183	0.000662	CcSEcCtD
Dexmedetomidine—Hypertension—Triamcinolone—psoriasis	0.000183	0.00066	CcSEcCtD
Dexmedetomidine—Infection—Hydrocortisone—psoriasis	0.000182	0.000658	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisolone—psoriasis	0.000182	0.000656	CcSEcCtD
Dexmedetomidine—Nausea—Hydroxyurea—psoriasis	0.000181	0.000653	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—psoriasis	0.00018	0.000649	CcSEcCtD
Dexmedetomidine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00018	0.000648	CcSEcCtD
Dexmedetomidine—Tachycardia—Hydrocortisone—psoriasis	0.000179	0.000646	CcSEcCtD
Dexmedetomidine—Somnolence—Mycophenolate mofetil—psoriasis	0.000179	0.000646	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000178	0.000643	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000177	0.00064	CcSEcCtD
Dexmedetomidine—Constipation—Cyclosporine—psoriasis	0.000177	0.000637	CcSEcCtD
Dexmedetomidine—Pain—Cyclosporine—psoriasis	0.000177	0.000637	CcSEcCtD
Dexmedetomidine—Dry mouth—Triamcinolone—psoriasis	0.000176	0.000636	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mycophenolic acid—psoriasis	0.000175	0.00063	CcSEcCtD
Dexmedetomidine—Angiopathy—Prednisone—psoriasis	0.000174	0.000629	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000174	0.000628	CcSEcCtD
Dexmedetomidine—Constipation—Mycophenolate mofetil—psoriasis	0.000172	0.000622	CcSEcCtD
Dexmedetomidine—Pain—Mycophenolate mofetil—psoriasis	0.000172	0.000622	CcSEcCtD
Dexmedetomidine—Arrhythmia—Prednisone—psoriasis	0.000172	0.00062	CcSEcCtD
Dexmedetomidine—Infection—Triamcinolone—psoriasis	0.000172	0.000619	CcSEcCtD
Dexmedetomidine—Hypotension—Hydrocortisone—psoriasis	0.000171	0.000619	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Cyclosporine—psoriasis	0.00017	0.000614	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000169	0.000609	CcSEcCtD
Dexmedetomidine—Dizziness—Mycophenolic acid—psoriasis	0.000169	0.000609	CcSEcCtD
Dexmedetomidine—Tachycardia—Triamcinolone—psoriasis	0.000169	0.000609	CcSEcCtD
Dexmedetomidine—Mental disorder—Prednisone—psoriasis	0.000168	0.000608	CcSEcCtD
Dexmedetomidine—Malnutrition—Prednisone—psoriasis	0.000167	0.000604	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Triamcinolone—psoriasis	0.000167	0.000603	CcSEcCtD
Dexmedetomidine—Convulsion—Dexamethasone—psoriasis	0.000166	0.000601	CcSEcCtD
Dexmedetomidine—Convulsion—Betamethasone—psoriasis	0.000166	0.000601	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000166	0.000599	CcSEcCtD
Dexmedetomidine—Hypertension—Dexamethasone—psoriasis	0.000166	0.000599	CcSEcCtD
Dexmedetomidine—Hypertension—Betamethasone—psoriasis	0.000166	0.000599	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000165	0.000594	CcSEcCtD
Dexmedetomidine—Abdominal pain—Cyclosporine—psoriasis	0.000163	0.000589	CcSEcCtD
Dexmedetomidine—Body temperature increased—Cyclosporine—psoriasis	0.000163	0.000589	CcSEcCtD
Dexmedetomidine—Anxiety—Betamethasone—psoriasis	0.000163	0.000588	CcSEcCtD
Dexmedetomidine—Anxiety—Dexamethasone—psoriasis	0.000163	0.000588	CcSEcCtD
Dexmedetomidine—Vomiting—Mycophenolic acid—psoriasis	0.000162	0.000586	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—psoriasis	0.000161	0.000583	CcSEcCtD
Dexmedetomidine—Rash—Mycophenolic acid—psoriasis	0.000161	0.000581	CcSEcCtD
Dexmedetomidine—Dermatitis—Mycophenolic acid—psoriasis	0.000161	0.00058	CcSEcCtD
Dexmedetomidine—Pain—Prednisolone—psoriasis	0.000161	0.00058	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—psoriasis	0.000161	0.00058	CcSEcCtD
Dexmedetomidine—Headache—Mycophenolic acid—psoriasis	0.00016	0.000577	CcSEcCtD
Dexmedetomidine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000159	0.000575	CcSEcCtD
Dexmedetomidine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000159	0.000575	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000158	0.000572	CcSEcCtD
Dexmedetomidine—Pain—Hydrocortisone—psoriasis	0.000157	0.000566	CcSEcCtD
Dexmedetomidine—Infection—Dexamethasone—psoriasis	0.000156	0.000562	CcSEcCtD
Dexmedetomidine—Infection—Betamethasone—psoriasis	0.000156	0.000562	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisolone—psoriasis	0.000155	0.000559	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—psoriasis	0.000155	0.000559	CcSEcCtD
Dexmedetomidine—Anaemia—Prednisone—psoriasis	0.000155	0.000558	CcSEcCtD
Dexmedetomidine—Dyspnoea—Triamcinolone—psoriasis	0.000154	0.000556	CcSEcCtD
Dexmedetomidine—Agitation—Prednisone—psoriasis	0.000154	0.000555	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Betamethasone—psoriasis	0.000153	0.000554	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Dexamethasone—psoriasis	0.000153	0.000554	CcSEcCtD
Dexmedetomidine—Tachycardia—Dexamethasone—psoriasis	0.000153	0.000552	CcSEcCtD
Dexmedetomidine—Tachycardia—Betamethasone—psoriasis	0.000153	0.000552	CcSEcCtD
Dexmedetomidine—Nausea—Mycophenolic acid—psoriasis	0.000152	0.000547	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Betamethasone—psoriasis	0.000152	0.000547	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Dexamethasone—psoriasis	0.000152	0.000547	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Hydrocortisone—psoriasis	0.000151	0.000546	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00015	0.000542	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—psoriasis	0.000149	0.000538	CcSEcCtD
Dexmedetomidine—Pain—Triamcinolone—psoriasis	0.000148	0.000533	CcSEcCtD
Dexmedetomidine—Hypotension—Dexamethasone—psoriasis	0.000146	0.000529	CcSEcCtD
Dexmedetomidine—Hypotension—Betamethasone—psoriasis	0.000146	0.000529	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—psoriasis	0.000146	0.000526	CcSEcCtD
Dexmedetomidine—Abdominal pain—Hydrocortisone—psoriasis	0.000145	0.000524	CcSEcCtD
Dexmedetomidine—Body temperature increased—Hydrocortisone—psoriasis	0.000145	0.000524	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisone—psoriasis	0.000145	0.000523	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—psoriasis	0.000145	0.000522	CcSEcCtD
Dexmedetomidine—Hypertension—Prednisone—psoriasis	0.000144	0.000521	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—psoriasis	0.000144	0.00052	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Triamcinolone—psoriasis	0.000142	0.000514	CcSEcCtD
Dexmedetomidine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000142	0.00538	CbGpPWpGaD
Dexmedetomidine—Anxiety—Prednisone—psoriasis	0.000142	0.000512	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cyclosporine—psoriasis	0.000141	0.00051	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—psoriasis	0.000141	0.000508	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—psoriasis	0.00014	0.000505	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000138	0.000497	CcSEcCtD
Dexmedetomidine—Body temperature increased—Triamcinolone—psoriasis	0.000137	0.000493	CcSEcCtD
Dexmedetomidine—Dizziness—Cyclosporine—psoriasis	0.000137	0.000493	CcSEcCtD
Dexmedetomidine—Infection—Prednisone—psoriasis	0.000136	0.00049	CcSEcCtD
Dexmedetomidine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000135	0.00514	CbGpPWpGaD
Dexmedetomidine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000135	0.000488	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000135	0.000488	CcSEcCtD
Dexmedetomidine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000135	0.00513	CbGpPWpGaD
Dexmedetomidine—Pain—Dexamethasone—psoriasis	0.000134	0.000484	CcSEcCtD
Dexmedetomidine—Pain—Betamethasone—psoriasis	0.000134	0.000484	CcSEcCtD
Dexmedetomidine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000134	0.00507	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—HCAR2—psoriasis	0.000133	0.00506	CbGpPWpGaD
Dexmedetomidine—Tachycardia—Prednisone—psoriasis	0.000133	0.000481	CcSEcCtD
Dexmedetomidine—Dizziness—Mycophenolate mofetil—psoriasis	0.000133	0.000481	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisone—psoriasis	0.000132	0.000476	CcSEcCtD
Dexmedetomidine—ADRA1B—GPCR ligand binding—HCAR2—psoriasis	0.000131	0.00498	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000131	0.00498	CbGpPWpGaD
Dexmedetomidine—Vomiting—Cyclosporine—psoriasis	0.000131	0.000474	CcSEcCtD
Dexmedetomidine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000131	0.00495	CbGpPWpGaD
Dexmedetomidine—Rash—Cyclosporine—psoriasis	0.00013	0.00047	CcSEcCtD
Dexmedetomidine—Dermatitis—Cyclosporine—psoriasis	0.00013	0.000469	CcSEcCtD
Dexmedetomidine—Headache—Cyclosporine—psoriasis	0.000129	0.000467	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—psoriasis	0.000129	0.000466	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Dexamethasone—psoriasis	0.000129	0.000466	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Betamethasone—psoriasis	0.000129	0.000466	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000128	0.000463	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Betamethasone—psoriasis	0.000128	0.000463	CcSEcCtD
Dexmedetomidine—Vomiting—Mycophenolate mofetil—psoriasis	0.000128	0.000462	CcSEcCtD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000128	0.00485	CbGpPWpGaD
Dexmedetomidine—Rash—Mycophenolate mofetil—psoriasis	0.000127	0.000458	CcSEcCtD
Dexmedetomidine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000127	0.000458	CcSEcCtD
Dexmedetomidine—Headache—Mycophenolate mofetil—psoriasis	0.000126	0.000455	CcSEcCtD
Dexmedetomidine—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000126	0.00477	CbGpPWpGaD
Dexmedetomidine—Diarrhoea—Hydrocortisone—psoriasis	0.000126	0.000453	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisolone—psoriasis	0.000124	0.000448	CcSEcCtD
Dexmedetomidine—Abdominal pain—Dexamethasone—psoriasis	0.000124	0.000447	CcSEcCtD
Dexmedetomidine—Body temperature increased—Betamethasone—psoriasis	0.000124	0.000447	CcSEcCtD
Dexmedetomidine—Body temperature increased—Dexamethasone—psoriasis	0.000124	0.000447	CcSEcCtD
Dexmedetomidine—Abdominal pain—Betamethasone—psoriasis	0.000124	0.000447	CcSEcCtD
Dexmedetomidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000123	0.00467	CbGpPWpGaD
Dexmedetomidine—Nausea—Cyclosporine—psoriasis	0.000123	0.000443	CcSEcCtD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—CCL20—psoriasis	0.000123	0.00465	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000122	0.00464	CbGpPWpGaD
Dexmedetomidine—ADRA1B—AMPK Signaling—LEP—psoriasis	0.000122	0.00463	CbGpPWpGaD
Dexmedetomidine—Dizziness—Hydrocortisone—psoriasis	0.000121	0.000438	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—psoriasis	0.000121	0.000437	CcSEcCtD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—NFKBIA—psoriasis	0.000121	0.00458	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.00012	0.00455	CbGpPWpGaD
Dexmedetomidine—Nausea—Mycophenolate mofetil—psoriasis	0.00012	0.000432	CcSEcCtD
Dexmedetomidine—Rash—Prednisolone—psoriasis	0.000118	0.000428	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisolone—psoriasis	0.000118	0.000427	CcSEcCtD
Dexmedetomidine—Headache—Prednisolone—psoriasis	0.000118	0.000425	CcSEcCtD
Dexmedetomidine—Constipation—Prednisone—psoriasis	0.000117	0.000421	CcSEcCtD
Dexmedetomidine—Vomiting—Hydrocortisone—psoriasis	0.000117	0.000421	CcSEcCtD
Dexmedetomidine—Rash—Hydrocortisone—psoriasis	0.000116	0.000418	CcSEcCtD
Dexmedetomidine—Dermatitis—Hydrocortisone—psoriasis	0.000116	0.000417	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—psoriasis	0.000115	0.000415	CcSEcCtD
Dexmedetomidine—Headache—Hydrocortisone—psoriasis	0.000115	0.000415	CcSEcCtD
Dexmedetomidine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000115	0.00435	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—CCL20—psoriasis	0.000115	0.00434	CbGpPWpGaD
Dexmedetomidine—Dizziness—Triamcinolone—psoriasis	0.000114	0.000412	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—psoriasis	0.000113	0.000409	CcSEcCtD
Dexmedetomidine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000113	0.00429	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000113	0.00429	CbGpPWpGaD
Dexmedetomidine—Feeling abnormal—Prednisone—psoriasis	0.000113	0.000406	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—psoriasis	0.000112	0.000403	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Prednisone—psoriasis	0.000112	0.000403	CcSEcCtD
Dexmedetomidine—Nausea—Prednisolone—psoriasis	0.000112	0.000403	CcSEcCtD
Dexmedetomidine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000111	0.00422	CbGpPWpGaD
Dexmedetomidine—Hyperhidrosis—Methotrexate—psoriasis	0.00011	0.000398	CcSEcCtD
Dexmedetomidine—Vomiting—Triamcinolone—psoriasis	0.00011	0.000396	CcSEcCtD
Dexmedetomidine—Nausea—Hydrocortisone—psoriasis	0.000109	0.000393	CcSEcCtD
Dexmedetomidine—Rash—Triamcinolone—psoriasis	0.000109	0.000393	CcSEcCtD
Dexmedetomidine—Dermatitis—Triamcinolone—psoriasis	0.000109	0.000393	CcSEcCtD
Dexmedetomidine—ADRA2A—GPCR ligand binding—HCAR2—psoriasis	0.000108	0.00411	CbGpPWpGaD
Dexmedetomidine—Headache—Triamcinolone—psoriasis	0.000108	0.000391	CcSEcCtD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000108	0.00409	CbGpPWpGaD
Dexmedetomidine—Abdominal pain—Prednisone—psoriasis	0.000108	0.00039	CcSEcCtD
Dexmedetomidine—Body temperature increased—Prednisone—psoriasis	0.000108	0.00039	CcSEcCtD
Dexmedetomidine—Diarrhoea—Dexamethasone—psoriasis	0.000107	0.000387	CcSEcCtD
Dexmedetomidine—Diarrhoea—Betamethasone—psoriasis	0.000107	0.000387	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—psoriasis	0.000107	0.000385	CcSEcCtD
Dexmedetomidine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00394	CbGpPWpGaD
Dexmedetomidine—Dizziness—Betamethasone—psoriasis	0.000104	0.000374	CcSEcCtD
Dexmedetomidine—Dizziness—Dexamethasone—psoriasis	0.000104	0.000374	CcSEcCtD
Dexmedetomidine—Nausea—Triamcinolone—psoriasis	0.000103	0.00037	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—psoriasis	0.000102	0.000367	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—psoriasis	0.000101	0.000366	CcSEcCtD
Dexmedetomidine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000101	0.00383	CbGpPWpGaD
Dexmedetomidine—Vomiting—Dexamethasone—psoriasis	9.97e-05	0.00036	CcSEcCtD
Dexmedetomidine—Vomiting—Betamethasone—psoriasis	9.97e-05	0.00036	CcSEcCtD
Dexmedetomidine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.9e-05	0.00375	CbGpPWpGaD
Dexmedetomidine—Rash—Betamethasone—psoriasis	9.88e-05	0.000357	CcSEcCtD
Dexmedetomidine—Rash—Dexamethasone—psoriasis	9.88e-05	0.000357	CcSEcCtD
Dexmedetomidine—Dermatitis—Dexamethasone—psoriasis	9.88e-05	0.000356	CcSEcCtD
Dexmedetomidine—Dermatitis—Betamethasone—psoriasis	9.88e-05	0.000356	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—psoriasis	9.85e-05	0.000356	CcSEcCtD
Dexmedetomidine—Headache—Betamethasone—psoriasis	9.82e-05	0.000354	CcSEcCtD
Dexmedetomidine—Headache—Dexamethasone—psoriasis	9.82e-05	0.000354	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—psoriasis	9.76e-05	0.000352	CcSEcCtD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.75e-05	0.0037	CbGpPWpGaD
Dexmedetomidine—Feeling abnormal—Methotrexate—psoriasis	9.4e-05	0.000339	CcSEcCtD
Dexmedetomidine—Diarrhoea—Prednisone—psoriasis	9.34e-05	0.000337	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—psoriasis	9.33e-05	0.000337	CcSEcCtD
Dexmedetomidine—Nausea—Dexamethasone—psoriasis	9.31e-05	0.000336	CcSEcCtD
Dexmedetomidine—Nausea—Betamethasone—psoriasis	9.31e-05	0.000336	CcSEcCtD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—CCL20—psoriasis	9.3e-05	0.00353	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.11e-05	0.00345	CbGpPWpGaD
Dexmedetomidine—Dizziness—Prednisone—psoriasis	9.03e-05	0.000326	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—psoriasis	9.02e-05	0.000326	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—psoriasis	9.02e-05	0.000326	CcSEcCtD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.96e-05	0.0034	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—HCAR2—psoriasis	8.95e-05	0.00339	CbGpPWpGaD
Dexmedetomidine—Vomiting—Prednisone—psoriasis	8.68e-05	0.000313	CcSEcCtD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.62e-05	0.00327	CbGpPWpGaD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—CXCL8—psoriasis	8.62e-05	0.00327	CbGpPWpGaD
Dexmedetomidine—Rash—Prednisone—psoriasis	8.61e-05	0.000311	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisone—psoriasis	8.6e-05	0.00031	CcSEcCtD
Dexmedetomidine—Headache—Prednisone—psoriasis	8.55e-05	0.000309	CcSEcCtD
Dexmedetomidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.53e-05	0.00324	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.48e-05	0.00321	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CCL20—psoriasis	8.22e-05	0.00312	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HCAR2—psoriasis	8.12e-05	0.00308	CbGpPWpGaD
Dexmedetomidine—Nausea—Prednisone—psoriasis	8.11e-05	0.000293	CcSEcCtD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—HCAR2—psoriasis	8.08e-05	0.00306	CbGpPWpGaD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—JUN—psoriasis	8.01e-05	0.00304	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	7.81e-05	0.00296	CbGpPWpGaD
Dexmedetomidine—Diarrhoea—Methotrexate—psoriasis	7.81e-05	0.000282	CcSEcCtD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—NFKB1—psoriasis	7.71e-05	0.00292	CbGpPWpGaD
Dexmedetomidine—Dizziness—Methotrexate—psoriasis	7.55e-05	0.000272	CcSEcCtD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—HCAR2—psoriasis	7.54e-05	0.00286	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.45e-05	0.00283	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—HCAR2—psoriasis	7.42e-05	0.00282	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CCL20—psoriasis	7.42e-05	0.00282	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.4e-05	0.0028	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HCAR2—psoriasis	7.33e-05	0.00278	CbGpPWpGaD
Dexmedetomidine—Vomiting—Methotrexate—psoriasis	7.25e-05	0.000262	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—psoriasis	7.19e-05	0.00026	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—psoriasis	7.19e-05	0.000259	CcSEcCtD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.17e-05	0.00272	CbGpPWpGaD
Dexmedetomidine—Headache—Methotrexate—psoriasis	7.15e-05	0.000258	CcSEcCtD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CCL20—psoriasis	6.93e-05	0.00263	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HCAR2—psoriasis	6.85e-05	0.0026	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CCL20—psoriasis	6.82e-05	0.00259	CbGpPWpGaD
Dexmedetomidine—Nausea—Methotrexate—psoriasis	6.78e-05	0.000245	CcSEcCtD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HCAR2—psoriasis	6.74e-05	0.00256	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.62e-05	0.00251	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.51e-05	0.00247	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—HCAR2—psoriasis	6.13e-05	0.00232	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—ITGAL—psoriasis	6.13e-05	0.00232	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	6.1e-05	0.00231	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	5.82e-05	0.00221	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—ITGAL—psoriasis	5.72e-05	0.00217	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CCL20—psoriasis	5.63e-05	0.00214	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.58e-05	0.00212	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.58e-05	0.00212	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HCAR2—psoriasis	5.56e-05	0.00211	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.5e-05	0.00209	CbGpPWpGaD
Dexmedetomidine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.23e-05	0.00198	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NDUFA5—psoriasis	5.15e-05	0.00195	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.12e-05	0.00194	CbGpPWpGaD
Dexmedetomidine—ADRA1B—AMPK Signaling—TP53—psoriasis	4.98e-05	0.00189	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HCAR2—psoriasis	4.8e-05	0.00182	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.75e-05	0.0018	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—ITGAL—psoriasis	4.65e-05	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CCL20—psoriasis	4.65e-05	0.00176	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.57e-05	0.00174	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.52e-05	0.00172	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP2S1—psoriasis	4.38e-05	0.00166	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HCAR2—psoriasis	4.33e-05	0.00164	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCL20—psoriasis	4.22e-05	0.0016	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CCL20—psoriasis	4.19e-05	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NDUFA5—psoriasis	4.18e-05	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TAGAP—psoriasis	4.16e-05	0.00158	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.15e-05	0.00157	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HCAR2—psoriasis	4.05e-05	0.00153	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HCAR2—psoriasis	3.98e-05	0.00151	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CCL20—psoriasis	3.92e-05	0.00149	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CCL20—psoriasis	3.86e-05	0.00146	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NDUFA5—psoriasis	3.84e-05	0.00146	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCL20—psoriasis	3.81e-05	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TAGAP—psoriasis	3.76e-05	0.00142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.75e-05	0.00142	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NDUFA5—psoriasis	3.62e-05	0.00137	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.56e-05	0.00135	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.56e-05	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCL20—psoriasis	3.56e-05	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP2S1—psoriasis	3.56e-05	0.00135	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.53e-05	0.00134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TAGAP—psoriasis	3.51e-05	0.00133	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCL20—psoriasis	3.5e-05	0.00133	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TAGAP—psoriasis	3.45e-05	0.00131	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.38e-05	0.00128	CbGpPWpGaD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—CXCL8—psoriasis	3.31e-05	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HCAR2—psoriasis	3.29e-05	0.00125	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP2S1—psoriasis	3.26e-05	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CCL20—psoriasis	3.18e-05	0.00121	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—CXCL8—psoriasis	3.09e-05	0.00117	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2S1—psoriasis	3.08e-05	0.00117	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.92e-05	0.00111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCL20—psoriasis	2.89e-05	0.0011	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TAGAP—psoriasis	2.85e-05	0.00108	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.82e-05	0.00107	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.72e-05	0.00103	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.64e-05	0.001	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.63e-05	0.000998	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—NOS2—psoriasis	2.51e-05	0.000953	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—CXCL8—psoriasis	2.51e-05	0.000953	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL20—psoriasis	2.49e-05	0.000945	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.46e-05	0.000933	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.42e-05	0.000918	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—NOS2—psoriasis	2.35e-05	0.00089	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.32e-05	0.000879	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.31e-05	0.000875	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL20—psoriasis	2.25e-05	0.000853	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CXCL8—psoriasis	2.22e-05	0.000842	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.21e-05	0.000839	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.15e-05	0.000816	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.14e-05	0.000813	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CARM1—psoriasis	2.14e-05	0.000811	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL20—psoriasis	2.1e-05	0.000797	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL20—psoriasis	2.07e-05	0.000785	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CXCL8—psoriasis	2e-05	0.00076	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2e-05	0.000757	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.96e-05	0.000744	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—NOS2—psoriasis	1.91e-05	0.000723	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CXCL8—psoriasis	1.87e-05	0.00071	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	1.84e-05	0.000699	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.84e-05	0.000696	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CARM1—psoriasis	1.74e-05	0.000658	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL20—psoriasis	1.71e-05	0.000648	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.61e-05	0.000612	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CARM1—psoriasis	1.59e-05	0.000605	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	1.52e-05	0.000577	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CARM1—psoriasis	1.5e-05	0.00057	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—VEGFA—psoriasis	1.46e-05	0.000552	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.4e-05	0.000533	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000521	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—VEGFA—psoriasis	1.36e-05	0.000516	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CAT—psoriasis	1.31e-05	0.000499	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—TYK2—psoriasis	1.31e-05	0.000496	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CXCL8—psoriasis	1.25e-05	0.000476	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SOCS1—psoriasis	1.24e-05	0.00047	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—TYK2—psoriasis	1.18e-05	0.000448	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SOCS1—psoriasis	1.16e-05	0.000439	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000432	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SOCS1—psoriasis	1.14e-05	0.000432	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	1.13e-05	0.00043	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CARM1—psoriasis	1.13e-05	0.000429	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—psoriasis	1.1e-05	0.000419	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—TYK2—psoriasis	1.1e-05	0.000419	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—psoriasis	1.1e-05	0.000417	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—TYK2—psoriasis	1.09e-05	0.000412	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CAT—psoriasis	1.07e-05	0.000405	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	1.06e-05	0.000401	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	1.04e-05	0.000395	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	1.03e-05	0.00039	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.03e-05	0.00039	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—psoriasis	1.03e-05	0.00039	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—APOE—psoriasis	1.02e-05	0.000387	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000384	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000384	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CAT—psoriasis	9.81e-06	0.000372	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	9.61e-06	0.000364	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CARM1—psoriasis	9.58e-06	0.000363	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	9.46e-06	0.000359	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	9.44e-06	0.000358	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SOCS1—psoriasis	9.4e-06	0.000357	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CAT—psoriasis	9.25e-06	0.000351	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—LEP—psoriasis	9.14e-06	0.000347	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APOE—psoriasis	9.14e-06	0.000347	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—TYK2—psoriasis	8.96e-06	0.00034	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.96e-06	0.00034	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PPARG—psoriasis	8.9e-06	0.000337	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	8.59e-06	0.000326	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APOE—psoriasis	8.54e-06	0.000324	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—LEP—psoriasis	8.54e-06	0.000324	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	8.52e-06	0.000323	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—LEP—psoriasis	8.41e-06	0.000319	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APOE—psoriasis	8.41e-06	0.000319	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—psoriasis	8.35e-06	0.000317	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APOE—psoriasis	8.3e-06	0.000315	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	7.96e-06	0.000302	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	7.83e-06	0.000297	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	7.8e-06	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TYK2—psoriasis	7.73e-06	0.000293	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APOE—psoriasis	7.62e-06	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—psoriasis	7.23e-06	0.000274	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOE—psoriasis	7.18e-06	0.000272	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TYK2—psoriasis	6.98e-06	0.000265	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAT—psoriasis	6.96e-06	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—LEP—psoriasis	6.94e-06	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOE—psoriasis	6.94e-06	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—psoriasis	6.73e-06	0.000255	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—psoriasis	6.64e-06	0.000252	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TYK2—psoriasis	6.52e-06	0.000247	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	6.47e-06	0.000245	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TYK2—psoriasis	6.42e-06	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—psoriasis	6.4e-06	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—psoriasis	6.26e-06	0.000237	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—psoriasis	6.26e-06	0.000237	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	6.08e-06	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NFKB1—psoriasis	6.02e-06	0.000228	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAT—psoriasis	5.89e-06	0.000224	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—psoriasis	5.78e-06	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—psoriasis	5.68e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—psoriasis	5.65e-06	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	5.59e-06	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—psoriasis	5.47e-06	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	5.44e-06	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—psoriasis	5.41e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOE—psoriasis	5.41e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—psoriasis	5.4e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—psoriasis	5.31e-06	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TYK2—psoriasis	5.3e-06	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—psoriasis	5.28e-06	0.0002	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—psoriasis	5.19e-06	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NFKB1—psoriasis	5.08e-06	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	5e-06	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	4.94e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—psoriasis	4.89e-06	0.000185	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—psoriasis	4.71e-06	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	4.61e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—psoriasis	4.61e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOE—psoriasis	4.58e-06	0.000174	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—psoriasis	4.56e-06	0.000173	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	4.54e-06	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—psoriasis	4.49e-06	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—psoriasis	4.38e-06	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—psoriasis	4.29e-06	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—psoriasis	4.13e-06	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.13e-06	0.000156	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—psoriasis	3.99e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—psoriasis	3.78e-06	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	3.74e-06	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—psoriasis	3.73e-06	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—psoriasis	3.71e-06	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—psoriasis	3.48e-06	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—psoriasis	3.43e-06	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—psoriasis	3.41e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—psoriasis	3.19e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—psoriasis	3.14e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—psoriasis	2.83e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—psoriasis	2.59e-06	9.82e-05	CbGpPWpGaD
